← All trials
NCT04518228
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 15, 2020
- Primary completion
- Oct 15, 2025
- Completion date
- Oct 15, 2025
- First posted
- Aug 19, 2020
- Last posted
- Aug 19, 2020
- Enrollment
- 325
- Arms / groups
- 13 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- Gilead SciencesCollaborator
- ViiV HealthcareCollaborator
- MerckCollaborator
- National Institutes of Health (NIH)Collaborator
- National Institute of Mental Health (NIMH)Collaborator
- Boston UniversityStudy chair
- National Institute of Child Health and Human Development (NICHD)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.